AbbVie Continues to Raise Quarterly Dividend Amid Patent Challenges

NodeGuardian · 2026-04-08T03:45:06+00:00

AbbVie has increased its quarterly dividend to $1.73 per share, supported by strong cash flow despite Humira's patent expiration. The company aims for $50 billion in sales from new drugs by 2030, with analysts optimistic about future earnings growth.

NodeGuardian

2026-04-08 03:45:06

Abstract generation in progress

AbbVie continues to raise its quarterly dividend, reaching $1.73 per share, or $6.92 annually, since its independence in 2013, demonstrating strong cash flow despite challenges from Humira’s patent expiration. The company is relying on new drugs like Skyrizi and Rinvoq, projected to hit $50 billion in sales by 2030, and growth in its neuroscience portfolio to sustain future profitability and dividend increases. Analyst sentiment is generally positive, with JPMorgan and RBC Capital maintaining positive ratings and price targets, anticipating significant earnings growth in 2026 and 2027.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes